PCI-27483

CAS No. 871266-63-6

PCI-27483 ( PCI27483; PCI-27483; PCI 27483 )

Catalog No. M17634 CAS No. 871266-63-6

PCI 27483 is an activated coagulation factor VIIa inhibitor with antithrombotic effects in a baboon model of arterial thrombosis.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 71 In Stock
10MG 120 In Stock
25MG 203 In Stock
50MG 306 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PCI-27483
  • Note
    Research use only, not for human use.
  • Brief Description
    PCI 27483 is an activated coagulation factor VIIa inhibitor with antithrombotic effects in a baboon model of arterial thrombosis.
  • Description
    PCI-27483 is a reversible small-molecule inhibitor of activated factor VII (factor VIIa) with potential antineoplastic and antithrombotic activities. FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, factor VIIa inhibitor PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells.
  • Synonyms
    PCI27483; PCI-27483; PCI 27483
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    Coagulation factor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    871266-63-6
  • Formula Weight
    596.57
  • Molecular Formula
    C26H24N6O9S
  • Purity
    98%
  • Solubility
    ——
  • SMILES
    c1cc2c(cc1C(=N)N)[nH]c(c1cc(cc(c1O)c1c(ccc(c1)S(=O)(=O)N)O)CC(=O)NC(CC(=O)O)C(=O)O)n2
  • Chemical Name
    (S)-2-(2-(5-(5-carbamimidoyl-1H-benzo[d]imidazol-2-yl)-2',6-dihydroxy-5'-sulfamoyl-[1,1'-biphenyl]-3-yl)acetamido)succinic acid.

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Gómez-Outes, A, et al. New parenteral anticoagulants in development. Ther. Adv. Cardiovasc. Disc. 5(1), 33-59 (2011).
molnova catalog
related products
  • iCDK9

    iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.

  • Purvalanol B

    A potent, cell-permeable, selective inhibitor of CDK with IC50s of 6, 6, 9, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, and cdk5-p35 respectively.

  • NU-2058

    An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.